Grant: Proof of Principle Program - Phase I
Université Laval
$148,348.00
Prognostic gene signature for stage I lung adenocarcinoma
FY 2012-13
Summary
Lung cancer is the leading cause of cancer-related deaths and is associated with a poor prognosis. Surgery remains the first line of treatment for a low stage non-small cell carcinoma (NSCLC). However, a significant percentage of these patients with low stage disease will eventually die after a relapse of their cancer. Prognostic factors for selecting patients for adjuvant chemotherapy following resection of a NSCLC is an urgent and unmet medical need. We aim at identifying prognostic gene expression signatures to predict relapse-free and overall survival. The original discovery made in this project was achieved using data from an ongoing genomic research program on lung diseases. Briefly, confirmed cases of NSCLC underwent lung resection at the Institut universitaire de cardiologie et de pneumologie de Québec. A non-tumor lung sample from each patient was harvested and analyzed using a whole-genome gene expression array. Clinical endpoints were also obtained including follow-up time, disease-free interval and survival. Analyses were carried out to identify genes that correlated with survival. A panel of genes was found to stratify patients in the high- or low-risk groups. A quantitative real-time PCR (qPCR) assay was developed for near-term clinical application. The goal of this project is to validate this new qPCR test in an independent set of samples. Ultimately, we aim to have a new genetic test that will guide adjuvant chemotherapy following lung resection for patients with a low stage NSCLC and implement this test in standard clinical care. The genetic test will be developed into a marketable application to optimize the management and treatment of patients with lung cancer.
Department
Program
Proof of Principle Program - Phase I
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
282880
Name
Bossé Yohan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Prognostic gene signature for stage I lung adenocarcinoma
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$148,348
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Commercialization Strategy; Gene Expression; Intellectual Property Protection; Lung Cancer; Market; Non-Tumor Lung Tissues; Patent; Prognosis; Qpcr; Socio-Economic Benefits
Abstract
Lung cancer is the leading cause of cancer-related deaths and is associated with a poor prognosis. Surgery remains the first line of treatment for a low stage non-small cell carcinoma (NSCLC). However, a significant percentage of these patients with low stage disease will eventually die after a relapse of their cancer. Prognostic factors for selecting patients for adjuvant chemotherapy following resection of a NSCLC is an urgent and unmet medical need. We aim at identifying prognostic gene expression signatures to predict relapse-free and overall survival. The original discovery made in this project was achieved using data from an ongoing genomic research program on lung diseases. Briefly, confirmed cases of NSCLC underwent lung resection at the Institut universitaire de cardiologie et de pneumologie de Québec. A non-tumor lung sample from each patient was harvested and analyzed using a whole-genome gene expression array. Clinical endpoints were also obtained including follow-up time, disease-free interval and survival. Analyses were carried out to identify genes that correlated with survival. A panel of genes was found to stratify patients in the high- or low-risk groups. A quantitative real-time PCR (qPCR) assay was developed for near-term clinical application. The goal of this project is to validate this new qPCR test in an independent set of samples. Ultimately, we aim to have a new genetic test that will guide adjuvant chemotherapy following lung resection for patients with a low stage NSCLC and implement this test in standard clinical care. The genetic test will be developed into a marketable application to optimize the management and treatment of patients with lung cancer.
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bossé, Yohan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $148,348~ $0~